Life Science Leader — April 2013 Outsourcing and the oral solid dose: Will challenges lead to new patterns of outsourcing? Life Science Leader — CRO Leadership Awards supplement issue Strategic Outsourcing Often Means Combining Functional and Full-Service CROs 
 
May 10 Life Science Leader's May issue includes results from Nice Insight annual research April 10 Learn about Trends in Outsourcing the Oral Solid Dose in April's Outsourcing Insights 
"Nice Insight's broad, unique set of data has allowed us to look at
pharmaceutical outsourcing from new angles, to provide perspectives to our
readers that they may not have considered before."
Paul Thomas Senior Editor, Pharmaceutical Manufacturing Magazine  
DIA 2013 49th Annual Meeting
June 23-27 Boston, MA |
Boehringer Ingelheim GmbH DSM Pharmaceutical Products Lonza Lupin Pharmaceuticals, Inc. Novasep Recipharm AB Roche Custom Biotech Therapure Biopharma, Inc. Kaneka America, LLC
Kaneka America, LLC manufactures pharmaceutical bulk intermediates and fine chemicals, especially in the field of chiral compounds. It utilizes enzyme mediated synthesis and fermentation technologies along with a variety of advanced organic synthesis technologies to manufacture a range of fine chemicals. Business activities span a range of markets: synthetic resins, resin products, chemicals, foodstuffs, pharmaceuticals, medical devices, electrical raw materials, and synthetic fibers. The company is a subsidiary of Kaneka Corporation. http://www.kaneka.com
Regions
Americas, Asia Stock Symbol Private Filter of Kaneka America, LLC's services per Nice Insight Categories
Contact Kaneka America, LLC 
|
|
|
